• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

A Fourth Booster May be Needed to Fight the Latest COVID Variant

Article

COVID-19's latest variant, omicron, could increase the chance that folks will need a fourth vaccine dose earlier than expected, according to executives at Pfizer.

COVID-19's latest variant, omicron, could increase the chance that folks will need a fourth vaccine dose earlier than expected, according to executives at Pfizer.

In a report by The Washington Post, Pfizer claimed early lab experiments suggest the standard two-dose regimen remains provides some protection against severe illness from the variant, and boosters are likely to control it.

Executives of Pfizer have said a fourth and necessary dose could be needed at least a year after a third, however more recently it's been said it could be sooner.

It's been stated by the CDC and the WHO, more than 40 people in the U.S. have tested positive for the omicron variant and that the variant has been Most showed mild reported in 57 countries so far.

Pfizer and BioNTech have been working on an Omicron-specific vaccine they hope to have available by March 2022 if the variant becomes widespread. Researchers started working on the new vaccine on Thanksgiving Day, Nov. 25, shortly after Omicron was identified.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.